{
    "nctId": "NCT01637103",
    "briefTitle": "Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy",
    "officialTitle": "Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Treatment of Depressive Symptoms in Cancer Patients",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 62,
    "primaryOutcomeMeasure": "Changes in depressive symptoms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* having received a diagnosis for a stage I-III cancer within the past 18 months;\n* having a score of 7 or higher on the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D)84 or of 14 or higher on the Beck Depression Inventory-II (BDI-II);\n\nExclusion Criteria:\n\n* have received bright light therapy in the past month or having previously received cognitive therapy for depression;\n* having severe cognitive impairments (e.g., diagnosis of Parkinson's disease, dementia, or Mini-Mental State Examination \\[MMSE\\] score \\< 27);\n* meeting DSM-IV criteria for a major depressive episode of severe intensity, or another severe psychiatric disorder (e.g., psychotic, bipolar, or substance use disorder);\n* presenting suicidal ideations with a risk of acting out, or having attempted suicide in the past five years;\n* having started a new psychotropic medication or having modified the dosage or frequency of use during the past two weeks;\n* currently taking a photosensitive medication (e.g., lithium, L-tryptophan);\n* having evidence of an ocular pathology from an optometrist exam or a medical condition contraindicating the use of bright light therapy (e.g., severe cataracts, glaucoma, diabetes).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}